Assessing Direct Oral Anticoagulants in the Clinical Laboratory.
Anti-Xa
Apixaban
Dabigatran
Direct oral anticoagulants (DOACs)
Edoxaban
Laboratory
Rivaroxaban
Journal
Clinics in laboratory medicine
ISSN: 1557-9832
Titre abrégé: Clin Lab Med
Pays: United States
ID NLM: 8100174
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
ppublish
Résumé
Direct oral anticoagulants (DOACs) have significant advantages over vitamin K antagonists including lack of need for routine laboratory monitoring. However, assessment of DOAC effect and concentration may be important to guide clinical management including need for DOAC reversal, particularly in acute or emergent situations. In this manuscript, the authors describe tests to screen for DOAC presence and tests that have demonstrated equivalence to gold standard testing for quantifying DOAC exposure. They also discuss the effect of DOACs on other coagulation assays and strategies for monitoring unfractionated heparin in patients with concomitant DOAC exposure.
Identifiants
pubmed: 39089758
pii: S0272-2712(24)00025-8
doi: 10.1016/j.cll.2024.04.014
pii:
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-562Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure R. C. Gosselin received consulting fees from Sysmex America, Inc. A. Cuker served as a consultant for MingSight, Sanofi, and Synergy and has received authorship royalties from UpToDate. There was no funders or funding sources for this article.